Latest news with #DavidDodd
Associated Press
11-06-2025
- Health
- Associated Press
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
GEO-MVA Provides Potential Opportunity to Expand Mpox Vaccine Supply Amid Growing U.S. and Global Clade 1 Threat ATLANTA, GA - June 11, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization's (WHO) fourth declaration of Mpox as a Public Health Emergency of International Concern (PHEIC). The WHO's decision reflects the ongoing global spread of the highly virulent Clade 1 strain of the Mpox virus, which has prompted heightened international concern and a call to action for more robust vaccine strategies. Mpox continues to pose a significant threat to global health, with WHO reporting rising case counts in endemic and non-endemic regions alike. In particular, Clade 1 Mpox - previously confined to Central Africa - is now appearing in Europe, Asia, and North America. In the United States, multiple confirmed Clade 1 cases have been reported across New York, California, Georgia, and New Hampshire. Additionally, Clade 1 viral particles have been detected in wastewater in North Carolina, California, Alabama and Iowa, suggesting silent transmission may be occurring even before symptomatic cases emerge. U.S. and Global Reliance on a Single Supplier Threatens Response Capacity Despite the urgency, the world remains dangerously dependent on a single manufacturer for the preferred Mpox vaccine, based on the Modified Vaccinia Ankara (MVA) platform. This presents significant risks to biosecurity, affordability, and equitable distribution. African nations alone have requested 20 million doses for 2025; global capacity is estimated at only 2–5 million doses annually. GEO-MVA: America's Strategic Vaccine Alternative GeoVax is actively developing GEO-MVA, a U.S.-based MVA vaccine for Mpox and smallpox. GEO-MVA is engineered as an alternative to the existing global supply and has been recognized at global forums as a pivotal component of future pandemic resilience. GeoVax has completed cGMP drug substance manufacturing of GEO-MVA, with fill/finish processes underway. Clinical vials are expected to be available in Q4 '25, enabling clinical trials to begin in 2026. GEO-MVA is also being developed using an advanced continuous avian cell line manufacturing process, intended to: 'WHO's latest declaration underscores that the Mpox crisis is not behind us - it is escalating,' said David Dodd, Chairman & CEO of GeoVax. 'As Clade 1 spreads in the U.S. and globally, we must act now to expand domestic vaccine capacity. Single-source dependency threatens access during geopolitical or logistical disruptions. GEO-MVA offers a scalable, cost-effective, and onshore alternative that supports national security, global equity, and pandemic preparedness.' Strengthening Biosecurity and Public Health Readiness GeoVax is engaged with U.S. federal agencies to align GEO-MVA with government initiatives aimed at onshoring critical pharmaceutical manufacturing and strengthening national pandemic readiness. The company's proposal under BARDA's Rapid Response Partnership Vehicle (RRPV) was selected for award, pending funding, to scale MVA-based vaccine production using advanced U.S. biomanufacturing technologies. GeoVax is calling on global and national policymakers to: About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696
Associated Press
21-05-2025
- Business
- Associated Press
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
GeoVax's Advanced MVA Manufacturing Platform Supports ASPR-DARPA Vision for Scalable, AI-Integrated Pharmaceutical Production ATLANTA, GA - May 21, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer, today welcomed the launch of the EQUIP-A-Pharma initiative - a new joint program between the U.S Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), the Defense Advanced Research Projects Agency (DARPA), and the private sector. This bold collaboration with private industry seeks to transform pharmaceutical manufacturing by leveraging artificial intelligence and next-generation platforms to expand U.S. production capacity and improve supply chain resilience. David Dodd, Chairman and CEO of GeoVax, commented: 'The EQUIP-A-Pharma initiative is a major step toward strengthening the domestic biomanufacturing backbone our country urgently needs. GeoVax has long championed the same goals this program now advances - self-reliant, scalable, and rapid production of critical medicines. Our advanced MVA manufacturing platform aligns perfectly with this mission, and we stand ready to support the federal government's vision of pharmaceutical independence and pandemic resilience.' GeoVax's Alignment with EQUIP-A-Pharma GeoVax is advancing a next-generation manufacturing platform for its Modified Vaccinia Ankara (MVA) vaccine technology - a platform that eliminates reliance on pathogen-free eggs and instead uses a continuous avian cell line system compatible with existing U.S. GMP infrastructure. This enables: The MVA platform underpins GeoVax's pipeline of multi-antigen vaccines, including its lead candidates GEO-CM04S1 (COVID-19) and GEO-MVA (Mpox and smallpox), and was recently selected under the Biomedical Advanced Research and Development Authority's Rapid Response Partnership Vehicle (RRPV) for further development, pending funding availability. A Strategic Partner for National Health Security GeoVax's domestic manufacturing strategy directly addresses vulnerabilities identified in recent biodefense reviews and the National Strategic Stockpile shortfalls highlighted by the Mpox outbreak. The Company continues to advocate for robust public-private collaboration to accelerate the deployment of resilient, U.S.-sourced medical countermeasures. Dodd concluded: 'GeoVax is committed to delivering scalable solutions that align with the Administration's priorities - from HHS to DARPA to BARDA. EQUIP-A-Pharma represents the future of biomanufacturing in the United States, and we are proud to be among the companies positioned to help build that future.' About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696
Yahoo
11-05-2025
- Business
- Yahoo
Bruker Corporation (BRKR): Among Michael Burry Stocks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Bruker Corporation (NASDAQ:BRKR) stands against other Michael Burry stocks with huge upside potential. Michael Burry, founder and manager of Scion Asset Management, is best known for predicting and profiting from the housing bubble's collapse in the mid-2000s. His bold contrarian bet was famously chronicled in the book and film 'The Big Short.' Burry's investment strategy draws heavily from the rigorous market analysis and principles outlined in Benjamin Graham and David Dodd's 1934 book 'Security Analysis.' The book championed the merits of financial statement analysis, highlighting the importance of intrinsic value and structured investment principles. That said, Burry has never shied away from putting his own distinct stamp on Wall Street's time-tested principles. By utilizing complex financial tools, such as derivative securities and short-selling, Burry has amassed a fortune, challenging conventional market wisdom. His 2001 Scion Value Fund letter provides a fascinating insight into his contrarian outlook, which prioritizes long-term value over short-term price fluctuations. Burry makes it clear that to achieve significant long-term returns, he is willing to tolerate short-term volatility. He stated: 'I will always choose the dollar bill carrying a wildly fluctuating discount rather than the dollar bill selling for a quite stable premium.' He also has no qualms about making significant investments in a few stocks that he believes are undervalued, a tactic the investor employed to strengthen Scion's holdings at the end of 2024. In the quarter that ended on December 31, 2024 just before DeepSeek's artificial intelligence breakthrough sparked a $1.3 trillion surge in Chinese tech stocks, Michael Burry offloaded some of his investments in the country's tech stocks. The moves came amid a period of high volatility for Chinese stocks, when investors appeared to be losing faith in Beijing following the implementation of a stimulus package in late September. The government's actions triggered a wild rally until early October, though momentum waned due to a property crisis, a poor economic outlook, and dissatisfaction with the scope of fiscal stimulus in the following months. For this article, we examined Scion Asset Management's Q4 2024 13F filings to list down Michael Burry's stock picks with the highest upside potential. We ranked the companies in ascending order of their upside potential. These equities are also popular among elite hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A scientist in a laboratory wearing safety gear while operating a mass spectrometry Corporation (NASDAQ:BRKR), a leading American manufacturer of high-performance scientific equipment, focuses on tools for molecular and materials research, as well as industrial analysis. Its innovative analytical and diagnostic solutions support life sciences, pharmaceuticals, and industrial applications by allowing for exploration at the molecular, cellular, and microscopic levels. Bruker Corporation (NASDAQ:BRKR) reported its Q1 2025 financial results on May 7, indicating strong revenue growth but declining earnings per share. The company reported revenue of $801.4 million, up 11% from $721.7 million for the same period in 2024. Acquisitions were the primary driver of this growth, accounting for 9.6% of the overall increase, while organic growth contributed 2.9%. Bruker Corporation (NASDAQ:BRKR) also launched the X4 POSEIDON, a new benchtop 3D X-ray microscope system designed to provide high-resolution imaging capabilities comparable to larger systems. Moreover, at the 21st Annual US HUPO Conference, the company announced substantial advances in proteomics technology, including improvements in single-cell proteomics and other areas. Overall, BRKR ranks 1st on our list of Michael Burry stocks with huge upside potential. While we acknowledge the potential for BRKR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BRKR but trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Business
- Yahoo
JD.com, Inc. (JD): Among Michael Burry Stocks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Inc. (NASDAQ:JD) stands against other Michael Burry stocks with huge upside potential. Michael Burry, founder and manager of Scion Asset Management, is best known for predicting and profiting from the housing bubble's collapse in the mid-2000s. His bold contrarian bet was famously chronicled in the book and film 'The Big Short.' Burry's investment strategy draws heavily from the rigorous market analysis and principles outlined in Benjamin Graham and David Dodd's 1934 book 'Security Analysis.' The book championed the merits of financial statement analysis, highlighting the importance of intrinsic value and structured investment principles. That said, Burry has never shied away from putting his own distinct stamp on Wall Street's time-tested principles. By utilizing complex financial tools, such as derivative securities and short-selling, Burry has amassed a fortune, challenging conventional market wisdom. His 2001 Scion Value Fund letter provides a fascinating insight into his contrarian outlook, which prioritizes long-term value over short-term price fluctuations. Burry makes it clear that to achieve significant long-term returns, he is willing to tolerate short-term volatility. He stated: 'I will always choose the dollar bill carrying a wildly fluctuating discount rather than the dollar bill selling for a quite stable premium.' He also has no qualms about making significant investments in a few stocks that he believes are undervalued, a tactic the investor employed to strengthen Scion's holdings at the end of 2024. In the quarter that ended on December 31, 2024 just before DeepSeek's artificial intelligence breakthrough sparked a $1.3 trillion surge in Chinese tech stocks, Michael Burry offloaded some of his investments in the country's tech stocks. The moves came amid a period of high volatility for Chinese stocks, when investors appeared to be losing faith in Beijing following the implementation of a stimulus package in late September. The government's actions triggered a wild rally until early October, though momentum waned due to a property crisis, a poor economic outlook, and dissatisfaction with the scope of fiscal stimulus in the following months. For this article, we examined Scion Asset Management's Q4 2024 13F filings to list down Michael Burry's stock picks with the highest upside potential. We ranked the companies in ascending order of their upside potential. These equities are also popular among elite hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A wide and imposing view of a supply chain distribution center, illustrating the company's technology Inc. (NASDAQ:JD) is a leading Chinese e-commerce company that focuses on computers and other electronic products, all the while serving as a supply chain-focused technology provider. Using its logistics network, has established itself as a major player in China's online retail market. On April 28, Citi analysts revised their outlook for Inc. (NASDAQ:JD), lowering the price target to $51 from $56 while maintaining a Buy rating on the company's stock. The adjustment comes after the company's order volume rose from 5 million to 10 million within a span of merely ten days, showing a strong push into the food delivery market. Inc. (NASDAQ:JD) announced its financial results for the fourth quarter and full year 2024 on March 6, 2025, indicating strong year-over-year growth in a number of critical areas. The company reported Q4 net revenues of RMB347.0 billion ($147.5 billion), up 13.4% from the same period in 2023. Full-year net revenues also came in at RMB1,158.8 billion ($158.8 billion), up 6.8% from the previous year. Patient Capital Opportunity Equity Strategy stated the following regarding Inc. (NASDAQ:JD) in its : 'We entered Inc. (NASDAQ:JD), a leading e-commerce company in China. Unlike competitors in the space, JD focuses on consumer electronics and home appliances supporting strong differentiation and defendable margins. The company has been on a year-long organizational restructuring following its ill-advised venture into the low-cost competitive space where it lacked an advantage. Not only will the company benefit from returning to their roots, but the government has rolled out a trade-in rebate policy for home appliances and consumer electronics further supporting demand. At the same time, the company has been disciplined in terms of spending, creating a margin expansion story as the topline demand improves. With the Chinese government increasing their focus on reigniting consumer consumption, we believe JD is well positioned to benefit from increased demand and improving margins. At the same time, the company is returning cash to shareholders via a dividend yield of 3.0%, and a buyback program that has seen 8.1% repurchased in 2024. While the risk of a trade war with China is an overhang on the stock, the company generates the majority of their revenues domestically.' Overall, JD ranks 3rd on our list of Michael Burry stocks with huge upside potential. While we acknowledge the potential for JD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than JD but trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-05-2025
- Business
- Yahoo
Magnera Corporation (MAGN): Among Michael Burry Stocks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Magnera Corporation (NYSE:MAGN) stands against other Michael Burry stocks with huge upside potential. Michael Burry, founder and manager of Scion Asset Management, is best known for predicting and profiting from the housing bubble's collapse in the mid-2000s. His bold contrarian bet was famously chronicled in the book and film 'The Big Short.' Burry's investment strategy draws heavily from the rigorous market analysis and principles outlined in Benjamin Graham and David Dodd's 1934 book 'Security Analysis.' The book championed the merits of financial statement analysis, highlighting the importance of intrinsic value and structured investment principles. That said, Burry has never shied away from putting his own distinct stamp on Wall Street's time-tested principles. By utilizing complex financial tools, such as derivative securities and short-selling, Burry has amassed a fortune, challenging conventional market wisdom. His 2001 Scion Value Fund letter provides a fascinating insight into his contrarian outlook, which prioritizes long-term value over short-term price fluctuations. Burry makes it clear that to achieve significant long-term returns, he is willing to tolerate short-term volatility. He stated: 'I will always choose the dollar bill carrying a wildly fluctuating discount rather than the dollar bill selling for a quite stable premium.' He also has no qualms about making significant investments in a few stocks that he believes are undervalued, a tactic the investor employed to strengthen Scion's holdings at the end of 2024. In the quarter that ended on December 31, 2024 just before DeepSeek's artificial intelligence breakthrough sparked a $1.3 trillion surge in Chinese tech stocks, Michael Burry offloaded some of his investments in the country's tech stocks. The moves came amid a period of high volatility for Chinese stocks, when investors appeared to be losing faith in Beijing following the implementation of a stimulus package in late September. The government's actions triggered a wild rally until early October, though momentum waned due to a property crisis, a poor economic outlook, and dissatisfaction with the scope of fiscal stimulus in the following months. For this article, we examined Scion Asset Management's Q4 2024 13F filings to list down Michael Burry's stock picks with the highest upside potential. We ranked the companies in ascending order of their upside potential. These equities are also popular among elite hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Michael Burry of Scion Asset ManagementMagnera Corporation (NYSE:MAGN), formed through the merger of Glatfelter and Berry's HH&S divisions, manufactures fiber-based engineered products. The company offers lightweight papers and composite fibers for a wide range of applications, including food and beverage, wall covering, technical specialties, composite laminates, and metallized products. Magnera Corporation (NYSE:MAGN) reported second-quarter earnings and revenue on May 7 that fell short of analyst expectations, while also lowering its full-year guidance. The company cited ongoing global economic uncertainty impacting results. According to CEO Curt Begle Magnera is 'prepared to take the appropriate operational and cost measures that align with short-term market realities' in the face of tariff-driven demand concerns. Looking forward, Magnera Corporation (NYSE:MAGN) reduced the range of its full-year comparable adjusted EBITDA guidance from $360 to $380 million. The company reiterated its post-merger adjusted free cash flow projection for fiscal 2025, standing at $75–$95 million. Kingdom Capital Advisors stated the following regarding Magnera Corporation (NYSE:MAGN) in its : 'Our most significant addition in Q4 was Magnera Corporation (NYSE:MAGN). The product of a merger between Glatfelter and Berry's HH&S businesses, Magnera began trading independently in November. The combined entity should file their 10-K shortly and report their Q1 in February, after which we expect the improvement in volumes for their non-wovens will become apparent. This is not an exciting business, producing products like wipes, diapers, etc. Magnera was spun with a significant amount of debt, but we interpret their upsized $800m notes offering as a sign that the business is turning. The debt is cheap, termed out, and backed by significant assets. We expect Management to focus on deleveraging quickly. As a bonus, some of their business lines were impacted by cheap imports in recent years, and I expect Magnera could be a beneficiary of a tougher tariff regime. At a high level, here is our investment framework: • Magenra should have about $1.8B of net debt after the spin, and 36m outstanding shares, with about $400m of EBITDA. Shares currently trade at $18. • I think Magnera can generate >$100m of annual FCF for the next three years, while growing EBITDA to $475-500m via synergies and volume recovery. These businesses have averaged over $500m of annual EBITDA in the past decade, suggesting this normalization is not overly aggressive. • At their current 6x EBITDA multiple, that would imply the business trades for $40/share within three years (~120% upside/30% IRR).' Overall, MAGN ranks 4th on our list of Michael Burry stocks with huge upside potential. While we acknowledge the potential for MAGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MAGN but trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
